GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model

Experimental Neurology

Volumn 263, Issue , 2015, Pages 177-189

  Hadaczek, Piotr ^a   Wu, Gusheng ^b   Sharma, Nitasha ^a   Ciesielska, Agnieszka ^a   Bankiewicz, Krystof ^a   Davidow, Amy L ^c   Lu, Zi Hua ^b   Forsayeth, John ^a   Ledeen, Robert W ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

B4galnt1; GDNF; GM1 analogs; GM1 ganglioside; LIGA20; Neuroprotection; Parkinson's disease; RET signaling

Indexed keywords

GANGLIOSIDE GM1; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PARVOVIRUS VECTOR; PROTEIN RET; GANGLIOSIDE; LIGA 20; SPHINGOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B4GALNT1 GENE; CONTROLLED STUDY; GENE; GENE DISRUPTION; GENE THERAPY; MOUSE; NONHUMAN; OCCIPITAL CORTEX; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; RISK FACTOR; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; DISEASE MODEL; GENE SILENCING; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; G(M1) GANGLIOSIDE; GANGLIOSIDES; GENE KNOCKDOWN TECHNIQUES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICE; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84910609998     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2014.10.010     Document Type: Article

References (65)

1. Akerud P., Canals J.M., Snyder E.Y., Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J. Neurosci. 2001, 21:8108-8118.
2. Bartels T., Kim N.C., Luth E.S., Selkoe D.J. N-alpha-acetylation of alpha-synuclein increases its helical folding propensity, GM1 binding specificity and resistance to aggregation. PLOS ONE 2014, 9:e103727.
3. Bespalov M.M., Sidorova Y.A., Tumova S., Ahonen-Bishopp A., Magalhaes A.C., Kulesskiy E., Paveliev M., Rivera C., Rauvala H., Saarma M. Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, and artemin. J. Cell Biol. 2011, 192:153-169.
4. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
5. Chao C.C., Ma Y.L., Chu K.Y., Lee E.H. Integrin αv and NCAM mediate the effects of GDNF on DA neuron survival, outgrowth, DA turnover and motor activity in rats. Neurobiol. Aging 2003, 24:105-116.
6. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997, 275:838-841.
7. Ciesielska A., Mittermeyer G., Hadaczek P., Kells A.P., Forsayeth J., Bankiewicz K.S. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 2011, 19:922-927.
8. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 2011, 12:359-366.
9. Crowder R.J., Enomoto H., Yang M., Johnson E.M., Milbrandt J. Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. J. Biol. Chem. 2004, 279:42072-42081.
10. Decressac M., Kadkhodaei B., Mattsson B., Laguna A., Perlmann T., Björklund A. α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl. Med. 2012, 4:163ra156.
11. Duchemin A.M., Ren Q., Mo L., Neff N.H., Hadjiconstantinou M. GM1 ganglioside induces phosphorylation and activation of Trk and Erk in brain. J. Neurochem. 2002, 81:696-707.
12. Eberling J.L., Kells A.P., Pivirotto P., Beyer J., Bringas J., Federoff H.J., Forsayeth J., Bankiewicz K.S. Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum. Gene Ther. 2009, 20:511-518.
13. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Annett L., Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 2005, 25:769-777.
14. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
15. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
16. Gimenez F., Krauze M.T., Valles F., Hadaczek P., Bringas J., Sharma N., Forsayeth J., Bankiewicz K.S. Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage 2011, 54:S189-S195.
17. Hadjiconstantinou M., Neff N.H. GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J. Neurochem. 1998, 70:1335-1345.
18. Hadjiconstantinou M., Rossetti Z.L., Paxton R.C., Neff N.H. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP. Neuropharmacology 1986, 25:1075-1077.
19. Hadjiconstantinou M., Mariani A.P., Neff N.H. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study. Brain Res. 1989, 484:297-303.
20. Johnston L.C., Eberling J., Pivirotto P., Hadaczek P., Federoff H.J., Forsayeth J., Bankiewicz K.S. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum. Gene Ther. 2009, 20:497-510.
21. Kells A.P., Forsayeth J., Bankiewicz K.S. Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol. Dis. 2012, 48:228-235.
22. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
23. Kordower J.H., Olanow C.W., Dodiya H.B., Chu Y., Beach T.G., Adler C.H., Halliday G.M., Bartus R.T. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136:2419-2431.
24. Kracun I., Rosner H., Drnovsek V., Vukelic Z., Cosovic C., Trbojevic-Cepe M., Kubat M. Gangliosides in the human brain development and aging. Neurochem. Int. 1992, 20:421-431.
25. Laganiere J., Kells A.P., Lai J.T., Guschin D., Paschon D.E., Meng X., Fong L.K., Yu Q., Rebar E.J., Gregory P.D., Bankiewicz K.S., Forsayeth J., Zhang H.S. An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J. Neurosci. 2010, 30:16469-16474.
26. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., Brooks D.J., Hotton G., Moro E., Heywood P., Brodsky M.A., Burchiel K., Kelly P., Dalvi A., Scott B., Stacy M., Turner D., Wooten V.G., Elias W.J., Laws E.R., Dhawan V., Stoessl A.J., Matcham J., Coffey R.J., Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 2006, 59:459-466.
27. Ledeen R.W., Wu G., Lu Z., Kozireski-Chubak D.F., Fang Y. The role of GM1 and other gangliosides in neuronal differentiation. Overview and new findings. Ann. N.Y. Acad. Sci. 1998, 845:161-175.
28. Lees M.B., Paxman S. Modification of the Lowry procedure for the analysis of proteolipid protein. Anal. Biochem. 1972, 47:184-192.
29. Leppänen V.M., Bespalov M.M., Runeberg-Roos P., Puurand U., Merits A., Saarma M., Goldman A. The structure of GFRalpha1 domain 3 reveals new insights into GDNF binding and RET activation. EMBO J. 2004, 23:1452-1462.
30. Martinez Z., Zhu M., Han S., Fink A.L. GM1 specifically interacts with α-synuclein and inhibits fibrillation. Biochem. 2007, 46:1868-1877.
31. Matsushita T., Elliger S., Elliger C., Podsakoff G., Villarreal L., Kurtzman G.J., Iwaki Y., Colosi P. Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998, 5:938-945.
32. Miyagi T., Wada T., Iwamatsu A., Hata K., Yoshikawa Y., Tokuyama S., Sawada M. Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides. J. Biol. Chem. 1999, 274:5004-5011.
33. Mocchetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell. Mol. Life Sci. 2005, 62:2283-2294.
34. Mutoh T., Tokuda A., Miyadai T., Hamaguchi M., Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5087-5091.
35. Mutoh T., Hamano T., Yano S., Tokuda A., Koga M., Yamamoto H., Furukawa K., Ledeen R.W. Stable transfection of GM1 synthase gene into GM1-deficient NG108-15 cells, CR-72 cells, rescues the responsiveness of Trk-neurotrophin receptor to its ligand, NGF. Neurochem. Res. 2002, 27:801-806.
36. Newburn E.N., Duchemin A.M., Neff N.H., Hadjiconstantinou M. GM1 ganglioside enhances Ret signaling in striatum. J. Neurochem. 2014, 130:541-554.
37. Ohmi Y., Ohkawa Y., Yamauchi Y., Tajima O., Furukawa K., Furukawa K. Essential roles of gangliosides in the formation and maintenance of membrane microdomains in brain tissues. Neurochem. Res. 2012, 37:1185-1191.
38. Paratcha G., Ledda F., Ibanez C.F. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 2003, 113:867-879.
39. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 2008, 11:755-761.
40. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 2005, 57:298-302.
41. Patel N.K., Pavese N., Javed S., Hotton G.R., Brooks D.J., Gill S.S. Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. Neurology 2013, 81:1176-1178.
42. Pitto M., Mutoh T., Kuriyama M., Ferraretto A., Palestini P., Masserini M. Influence of endogenous GM1 ganglioside on TrkB activity, in cultured neurons. FEBS Lett. 1998, 439:93-96.
43. Radin N.S., Shayman J.A., Inokuchi J.I. Metabolic effects of inhiting glucosylceramide synthesis with PDMP and other substances. Adv. Lipid Res. 1993, 26:183-213.
44. Rosenblad C., Martinez-Serrano A., Bjorklund A. Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998, 82:129-137.
45. Schneider J.S., DiStefano L. Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion. Neuropharmacology 1995, 34:489-493.
46. Schneider J.S., Pope A., Simpson K., Taggart J., Smith M.G., DiStefano L. Recovery from experimental Parkinsonism in primates with GM1 ganglioside treatment. Science 1992, 256:843-846.
47. Schneider J.S., Kean A., DiStefano L. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J. Neurosci. Res. 1995, 42:117-123.
48. Schneider J.S., Sendek S., Daskalakis C., Cambi F. GM1 ganglioside in Parkinson's disease: results of a five year open study. J. Neurol. Sci. 2010, 292:45-51.
49. Schneider J.S., Gollomp S.M., Sendek S., Colcher A., Cambi F., Du W. A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J. Neurol. Sci. 2013, 324:140-148.
50. Segler-Stahl K., Webster J.C., Brunngraber E.G. Changes in the concentration and composition of human brain gangliosides with aging. Gerontology 1983, 29:161-168.
51. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J. Neurosurg. 2005, 102:216-222.
52. Svennerholm L., Bostrom K., Fredman P., Mansson J.E., Rosengren B., Rynmark B.M. Human brain gangliosides: developmental changes from early fetal stage to advanced age. Biochim. Biophys. Acta 1989, 1005:109-117.
53. Svennerholm L., Bostrom K., Jungbjer B., Olsson L. Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100years. J. Neurochem. 1994, 63:1802-1811.
54. Tansey M.G., Baloh R.H., Milbrandt J., Johnson E.M. GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 2000, 25:611-623.
55. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
56. Trupp M., Belluardo N., Funakoshi H., Ibanez C.F. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J. Neurosci. 1997, 17:3554-3567.
57. Wright J.F., Qu G., Tang C., Sommer J.M. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr. Opin. Drug Discovery Dev. 2003, 6:174-178.
58. Wu G., Lu Z., Xie X., Li L., Ledeen R.W. Mutant NG108-15 cells (NG-CR72) deficient in GM1 synthase respond aberrantly to axonogenic stimuli and are vulnerable to calcium-induced apoptosis: they are rescued with Liga-20. J. Neurochem. 2001, 76:690-702.
59. Wu G., Xie X., Lu Z., Ledeen R.W. Cerebellar neurons lacking complex gangliosides degenerate in the presence of depolarizing levels of potassium. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:307-312.
60. Wu G., Lu Z., Wang J., Wang Y., Xie X., Meyenhofer M.F., Ledeen R.W. Enhanced susceptibility to kainate-induced seizures, neuronal apoptosis and death in mice lacking gangliotetraose gangliosides. Protection by LIGA 20, a permeant analog of GM1. J. Neurosci. 2005, 25:11014-11022.
61. Wu G., Lu Z.H., Kulkarni N., Amin R., Ledeen R.W. Mice lacking major brain gangliosides develop parkinsonism. Neurochem. Res. 2011, 36:1707-1714.
62. Wu G., Lu Z.H., Gabius H.J., Ledeen R.W., Bleich D. Ganglioside GM1 deficiency in effector T cells from NOD mice induces resistance to regulatory T-cell suppression. Diabetes 2011, 60:2341-2349.
63. Wu G., Lu Z.H., Kulkarni N., Ledeen R.W. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans. J. Neurosci. Res. 2012, 90:1997-2008.
64. Xie X., Wu G., Lu Z., Ledeen R.W. Potentiation of a sodium-calcium exchanger in the nuclear envelope by nuclear GM1 ganglioside. J. Neurochem. 2002, 81:1185-1195.
65. Yamada S., Nomura T., Uebersax L., Matsumoto K., Fujita S., Miyake M., Miyake J. Retinoic acid induces functional c-Ret tyrosine kinase in human neuroblastoma. Neuroreport 2007, 18:359-363.